Open Access

Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico

  • Lilia Gonzalez-Ceron1Email author,
  • Mario H. Rodriguez2,
  • Marco A. Sandoval1,
  • Frida Santillan1,
  • Sonia Galindo-Virgen3,
  • Angel F. Betanzos2,
  • Angel F. Rosales1 and
  • Olga L. Palomeque1
Malaria Journal201514:426

https://doi.org/10.1186/s12936-015-0938-2

Received: 4 May 2015

Accepted: 9 October 2015

Published: 30 October 2015

Abstract

Background

In Mexico, combined chloroquine (CQ) and primaquine (PQ) treatment has been used since the late 1950s to treat Plasmodium vivax infections. Although malaria transmission has declined, current treatment strategies must be evaluated to advance towards malaria elimination.

Methods

The clinical and parasitological outcome of treating symptomatic P. vivax with the 14-day (T14) treatment or intermittent single dose (ISD) regimen was evaluated in southern Mexico between February 2008 and September 2010. Patients over 12 months old with P. vivax mono-infection and asexual parasitaemia ≥500 parasites/µl were treated under supervision. After diagnosis (day 0), treatment began immediately. T14 patients received CQ for 3 days (10, 10 and 5 mg/kg) and PQ daily for 14 days (0.25 mg/kg), while ISD patients received a single dose of CQ (10 mg/kg) and PQ (0.75 mg/kg) on days 0, 30, 60, 180, 210, and 240. Follow-up was done by observing clinical and laboratory (by microscopy, serology and PCR) outcome, considering two endpoints: primary blood infection clearance and clinical response at ~28 days, and the incidence of recurrent blood infection during 12 months. Parasite genotypes of primary/recurrent blood infections were analysed.

Results

During the first 28 days, no differences in parasite clearance or clinical outcome were observed between T14 (86 patients) and ISD (67 patients). On day 3, 95 % of patients in both groups showed no blood parasites, and no recurrences were detected on days 7–28. Contrarily, the therapeutic effectiveness (absence of recurrent parasitaemia) was distinct for T14 versus ISD at 12 months: 83.7 versus 50 %, respectively (p = 0.000). Symptomatic and asymptomatic infections were recorded on days 31–352. Some parasite recurrences were detected by PCR and/or serological testing.

Conclusions

T14 was effective for opportune elimination of the primary blood infection and preventing relapse episodes. The first single dose of CQ-PQ eliminated primary blood infection as efficiently as the initial three-dose scheme of T14, but the ISD regimen should be abandoned. A single combined dose administered to symptomatic patients in remote areas while awaiting parasitological diagnosis may contribute to halting P. vivax transmission. Alternatives for meeting the challenge of T14 supervision are discussed.

Trial registration: NIH-USA, ClinicalTrial.gov Identifier: NCT02394197

Keywords

Plasmodium vivax ChloroquinePrimaquineEffectivenessSingle doseISDT14MicroscopyPCRSerologyRelapseGenotypeSouthern Mexico

Background

According to malaria records, which have existed in Mexico since 1949, the last epidemic occurred in the 1980s. At that time, more than 120,000 cases were reported each year and malaria transmission was present in over 50 % of the country. Due to the intensification of control activities, transmission has now been reduced to a few residual foci. In fact, local transmission of Plasmodium falciparum was completely eliminated in 2000, the same year in which 7259 Plasmodium vivax cases were reported. The number of cases of the latter Plasmodium species was reduced to 2702 in 2009. The country is currently considered to be in the pre-elimination phase [14].

In most affected areas around the world, a combination treatment of chloroquine (CQ) and primaquine (PQ) was introduced in the 1950s to treat P. vivax blood and liver infections [5, 6]. In regions where parasites are susceptible to these drugs, the recommended doses are the following: CQ at 25 mg/kg bw (body weight) during three consecutive days (10, 10 and 5 mg/kg bw) and PQ at 0.25–0.75 mg/kg bw during 14 days [7, 8]. In fact, this 14-day (T14) treatment effectively cures primary blood infections and is the most effective for preventing relapses [9]. However, in areas where CQ is no longer effective, it is recommended that artemisinin combination therapy (ACT) be used instead, also in combination with PQ for radical cure [8]. No studies exist on CQ resistance in Mexico.

Like most of the Americas, Mexico has been using the combination of CQ and PQ as the standard treatment for P. vivax malaria to date. However, PQ treatment is frequently not completed due to its undesirable side effects. Although haemolysis due to glucose 6-phosphate dehydrogenase deficiency (G6PDd) in PQ-treated patients is a concern in malaria-affected regions [8], the Mexican Malaria Control Programme (MCP) has administered 0.75 mg PQ in a single dose for decades without G6PDd testing [10]. In this country, G6PDd occurs in less than 1 % of the general population (the African-related variant is the most common) [1113].

In locations of difficult access, the intervals between blood sampling, parasitological diagnosis and patient treatment used to be as long as 3–4 weeks. Hence, to reduce the risk of transmission, febrile patients were blood sampled and immediately treated with a single dose of 10 mg of CQ and 0.75 mg of PQ per kg bw [14, 15]. Then, after microscopy confirmation, the full T14 treatment was administered. In 1999, an intermittent single dose regimen (ISD) replaced T14. The ISD regimen, allegedly easy to dispense under field conditions, comprises monthly administration of a single dose for 3 months, followed by 3 months without dosing. This schedule is repeated twice each year to complete 3 years of treatment, with a total of 18 doses [10, 16, 17].

The first single combined CQ-PQ dose is expected to eliminate blood parasites, since PQ may destroy parasites surviving from the effect of CQ [15, 18, 19]. The repeated administration of ISD was intended to suppress cases of recurrent parasitaemia [10, 17]. However, symptomatic recurrent infections in southern Mexico (probably relapses) have been detected within 12 months of the initial treatment [20]. Assessment and monitoring of the effectiveness of T14 and ISD treatment is necessary in order to assess their efficacy and contribution to malaria reduction, with the aim of advancing towards malaria elimination in the region [21]. The aim of the present study was to compare the effectiveness of the standard T14 treatment with that of the ISD regimen in patients living in endemic communities of southern Mexico. Two endpoints were considered: their efficacy in clearing primary clinical and parasitological infections within 28 days post-diagnosis, and in treating recurrent P. vivax infections during a 12-month period.

Methods

The protocol of this study was approved by the Ethics in Research Review Committee of the National Institute of Public Health (Mexico). Informed consent was obtained from all patients or the guardians of minors.

Study design

An open-labelled, non-randomized, clinical trial was conducted with a group of malaria patients receiving a combined dose of CQ and PQ with either an ISD schedule or the standard 14-day treatment (T14). In both cases, the first dose was given on day 0, the day of diagnosis. The treatment dosing was adjusted according to the age group of a patient, as recommended by the Mexican MCP for ISD and T14 [10]. The study was designed to evaluate two clinical and parasitological endpoints: the primary parasite blood infection clearance and clinical response at ~28 days post-diagnosis, and the incidence of recurrent blood infections during 12 months.

Study site

The study was carried out in the Tapachula municipality and surrounding communities in southern Chiapas, Mexico, a region on the Guatemala border with an altitude ranging from ~50–1200 meters above sea level. This is a hypo-endemic region showing variable malaria incidence, with an annual parasite incidence (API) of 0.579–1.523 cases/1000 inhabitants when considering only the affected villages for the period 2003–2007 (data from the Local Sanitary Jurisdiction VII). Patient recruitment was carried out in the diagnosis facility at the Regional Centre for Public Health Research-INSP (CRISP) in Tapachula City, where febrile individuals seeking malaria diagnosis and treatment can obtain free service.

Patients

Patients were recruited from February 2008 to October 2009 and the follow-up ended in September 2010. Inclusion criteria were: (1) patients over 12 months old; (2) P. vivax mono-infection, confirmed by microscopy; (3) parasite densities of 500-50,000/μl of blood; and, (4) elevated axillary temperature (≥37.5 °C) or a history of a fever episode within the previous 48 h. Patients were excluded if they: (1) lived in communities that could not be reached by travelling for 1 h by motor vehicle from the CRISP centre; (2) presented signs of severe malnutrition or anaemia; (3) had taken an anti-malaria treatment or had had a malaria infection within the previous 12 months (to reduce the probability of incorporating patients with a relapse) [20]; (4) had another possible cause for their fever or suffered from some chronic disease; (5) were allergic to CQ; or, (6) were pregnant (by patient statement and/or pregnancy test of women over 14) [7]. The pregnancy test consisted of a urine sample evaluated with Gestastrip II (Hycel, Jalisco, Mexico).

For practical purposes, patients were not randomized to form the two treatment groups (ISD and T14). Patients living in Tapachula City and the nearby area were preferred to administer the T14 treatment in order to facilitate daily supervision. On the day of diagnosis (day 0), patients were examined for axillary temperature, body weight, spleen swelling, and clinical symptoms such as fever, headache, myalgia, arthralgia, erythema, and jaundice. Capillary blood, collected by finger pricking, was used to prepare thin and thick smears and to impregnate filter paper (Whatman #2) for parasitological and serological (DNA and antibody) analysis, respectively.

Patient treatment and follow-up

For the ISD regimen, the standard single dose consisted of 10 mg/kg of CQ and 0.75 mg/kg of PQ, which the patients were scheduled to take on days 0, 30, 60, 180, 210, and 240. For the T14 treatment, the optimal dose was 25 mg/kg of CQ administered over a three-day period (10 mg/kg on days 0 and 1 and 5 mg/kg on day 2) and PQ at 0.25 mg/kg/day given during 14 days [7, 8]. However, both treatment regimens were adjusted to the age group of patients, according to the operational table prescribed by the Mexican official guidelines (Additional file 1) [10]. For small children, tablets were crushed, mixed with water and spoon fed. Treated patients were observed during 30 min after ingesting the drugs. Those who vomited the first dose were re-treated with a similar dose, and those who vomited again were treated, but excluded from the study.

The CQ and PQ tablets were provided by the local malaria control programme (drug batches used during the study are shown in Additional file 2). The first dose was administered immediately after diagnosis at CRISP (day 0), and all subsequent doses were administered under supervision by a member of the study team. If a patient was not available to receive one or two supervised doses, these were left with a family member. If the next day the patient claimed to have taken the dose and was willing to continue with the medication and follow-up, he/she remained in the study within the semi-supervised group.

In case of feeling ill (having fever or presenting one of two other malaria symptoms) at any time during the follow-up period, patients were encouraged to visit the facility at CRISP or to contact the field team by mobile phone (most patients or their parents had a mobile phone). The same recommendation was given in the event that patients had any question about the study. Whether during the treatment or follow-up period, participants unable to reach the facility were visited at their homes for treatment, clinical revision and blood sampling. All treated patients were scheduled for examination on days 2, 3, 7, 14, 21, and 28 [22]. Afterwards, parasitological and clinical examinations were implemented monthly until completing the 12-month protocol. When required, scheduling changes were made to complete the follow-up for each patient, as suggested by Ruebush et al. [23]. If patients, after the first ISD administration, were not at home on day 3, they were visited on day 4. Likewise, visits were made on day 7 ± 1, and on day 14 ± 2. For all patients (under ISD or T14), a visit was carried out on day 21 ± 2, and so on for the rest of the follow-up.

Two thick and thin blood films and a sample of blood impregnated in filter paper (Whatman #2) were prepared at every scheduled or extra visit. Patients with axillary temperatures ≥37.5 °C were symptomatically treated with paracetamol (acetaminophen) (10 mg/kg). A rapid diagnostic test (RDT) OptiMAL© [24] was applied to symptomatic patients when visited at home. Thick smears of symptomatic patients with negative RDT were analysed the same day and if a recurrent P. vivax episode was confirmed, they were immediately treated with T14 [8].

Parasitological diagnosis

Thick and thin blood smears were stained with 10 % Giemsa (pH 7.2) for 5 min. The two thick smears were independently examined under a light microscope by two trained laboratory technicians by using oil immersion 100×. Asexual and sexual parasite densities were determined by counting the number of parasites found per 200 white blood cells (WBC) assuming 7000 WBC/μl of blood [24, 25]. In case of very light infections (less than 10 parasites/200 WBC), 500 WBC were inspected to confirm the counts. At least 500 fields were examined to record a sample as negative. One thick smear was analysed at CRISP and the second one by another microscopist at the Institute of Diagnosis and Epidemiological Reference, the national reference laboratory of quality control for malaria diagnosis in Mexico. Discrepancies on smears results (absence versus presence of parasites or counts differing by 50 %) were resolved by cross validation, examined by a third experienced microscopist. Asexual parasitaemia was quantified using the following formula: parasites/µl of blood = (number of parasites per 200/500 fields × 7000 WBC per 1 µl of blood)/number of WBC per 200/500 fields.

Molecular diagnosis (PCR)

Molecular diagnosis has proven to be very sensitive in different regions affected by malaria [26, 27]. All blood samples (whether taken on days 2, 3, 7, 14, ~21, or ~28, or thereafter during the monthly examinations) with an increase in the anti-P. vivax IgG antibody titre (ELISA OD value), were subjected to molecular diagnosis due to suspicion of recent malaria infection. Six 5-mm punches of filter paper impregnated with dried blood were used to extract DNA, using the QIAamp® DNA Blood Mini Kit (QIAGEN, Hilden, Germany) and following the manufacturer’s instructions. The DNA obtained was suspended in 50 µl of water and stored at −20 °C until used. The presence of the P. vivax 18S small sub-unit ribosomal RNA gene was assessed as previously reported [28]. Infected (with P. vivax: 500, 2000 and 10,000 p/µl) and uninfected blood samples were included as controls.

Detection of IgG antibodies against the Plasmodium vivax blood stage (by ELISA)

Antibodies against the P. vivax blood stage can last for months or years in exposed patients. However, antibody titres fade out more rapidly in treated patients [2931]. To reveal P. vivax re-exposure, with and without clinical symptoms and/or low parasitaemia in recurrent blood infections, retrospective research was conducted at the end of the 12-month follow-up period to look for native P. vivax blood-stage proteins in preserved blood samples by using ELISA, as previously reported [32]. Briefly, the blood samples that had been taken from each patient and smeared on filter paper were eluted in PBS and tested at 1:500 dilutions in an indirect ELISA. The reaction was revealed using goat anti-human IgG (H + L)-HRP (Pierce, Rockford, IL, USA) diluted 1:5000 and ABTS (2,2′-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt) as substrate for 60 min, and then OD values were recorded in a spectrophotometer (Biotek® model EL312) at 405 nm. Cut-off values were previously determined using unexposed individuals as the mean and 2SD as 0.25 OD values (95 % confidence). The ELISA-OD values were plotted according to time point per patient.

Primary and recurrent Plasmodium vivax genotype determination

To determine the frequency of parasite genotypes, all P. vivax infected blood was analysed for cspr and msp3α by polymerase chain reaction and restriction fragment length polymorphism (PCR–RFLP) [20]. The homogeneity of P. vivax genotypes among groups was examined by Fisher’s exact test (α = 0.05). In addition to cspr and msp3α, parasite genotypes were analysed using msp3β after Alu I digestion to compare parasites producing primary and secondary episodes in each patient [33].

Data analysis

For each patient that completed the supervised treatments and the follow-up (for 28 days and 12 months post-diagnosis), parasitological and clinical data were analysed using STATA v12. To discard the possibility that a sub-dose caused delay in parasite clearance, the body weight recorded on day 0 was used to determine the accuracy of doses of CQ and PQ given to patients using age group dosing.

The first endpoint, parasitological and clinical cure of the primary blood infection, was evaluated by determining the early clinical and parasitological outcome at 2–3 days post-diagnosis, and the possible clinical and/or parasitological asexual parasite persistence or reappearance within seven to 28 days post-diagnosis. Therapeutic failure (TF) was defined as the presence of parasitaemia, while an adequate clinical and parasitological response (ACPR) was considered with the absence of parasites on days 7–28: for these analyses, both microscopic and PCR results were included.

Fisher’s exact test was used to compare two or more independent proportions between treatment groups, considering gender, PCR positivity, parasite persistence, the presence of symptoms, and the distribution of the P. vivax genotype on day 2 or 3. The Wilcoxon rank sum test was used for non-parametric comparisons: age, asexual and sexual parasitaemia, drug doses, number of days of symptoms, and axial temperature. All tests of significance were two-tailed and P values < 0.05 were considered statistically significant.

The second endpoint evaluated was by determining whether or not recurrent blood infections existed during the follow-up ending 12 months after day 0. The effectiveness was calculated as the per cent of the accumulated number of patients without P. vivax blood infection (first recurrent case) detected at each month of sampling, divided by the total number of patients followed up. The Z-test was used to determine differences in the proportion of patients or samples with a recurrent infection. To plot the cumulative incidence of patients with the first recurrence, the Kaplan–Meier failure estimate was used.

Results

Demographics, clinical and parasitological characteristics of patients

During the recruitment period, the diagnostic facility at CRISP received 1,820 symptomatic patients, of which 343 were diagnosed with P. vivax by microscopy. Of the 153 self-reporting malaria-symptomatic patients that satisfied the inclusion criteria, 86 received the T14 treatment and 67 the ISD regimen (Fig. 1). More patients were assigned to T14, expecting that several patients would not complete all supervised T14 doses. The proportion of gender and median age of participants, median and interquartile range (IQR) of the duration of symptoms (in days), and parasite densities were similar in both groups (Table 1). There was no difference in the proportion of patients indicating certain malaria symptoms, such as fever, headache, myalgia, arthralgia, chills, jaundice, blisters, and erythema (Table 1).
Fig. 1

Flow chart of Plasmodium vivax patient detection and recruitment for T14 and ISD treatment regimens, in southern Mexico. D day

Table 1

Characteristics of patients participating in the study: CQ–PQ combined treatment in 14 days (T14) and intermittent single doses (ISD)

Parameters

By regimen of anti-malarial treatment

P value

Single doses (ISD)

14-day (T14)

Total patients

67

86

 

By Gender (n)

 

Female

Male

Female

Male

0.274 a

Age range in years

 1–5

2

3

2

3

Age by gender (male/age, 0.58; female/age, 0.413)

 6–15

13

6

6

13

 16–25

6

6

9

9

 26–40

4

6

9

12

 >40

9

12

10

13

Total

34

33

36

50

 

Body weight: median (IQR), range

50 (25), 9.6–108

57 (20), 14–104

0.219 b

Days of symptoms: median (IQR), range

5 (4), 1–20

4 (4), 1–30

0.265 b

Axial temperature (°C): median (IQR), range

37.45 (1.1), 36–40

37.5 (1), 36.5–40.1

0.183 b

Asexual parasitaemia/µl: median (IQR), range

4888 (5379), 512–28,940

3830 (5443), 490–28,424

0.20 b

Samples with gametocytes

100 %

100 %

0.073 b

Gametocytaemia/µl: median (IQR), range

697 (959), 45–5684

999 (1305), 35-12,102

Clinical symptoms indicated by patients as having occurred within 2 days of arrival to our diagnosis facility (% of patients indicating each condition)

0.265 c

 Fever

98.1

100

 

 Headache

98.1

96.5

 

 Mialgias

89.5

89.5

 

 Arthralgias

80.6

83.7

 

 Paroxysm

77.6

68.6

 

 Jaundice

11.9

12.8

 

 Blisters

2.9

3.4

 

 Pruritus

0

0

 

F female, M male, n number of patients, IQR interquartile range

aChi square; α = 0.05

bTwo-sample Wilcoxon rank-sum (Mann–Whitney) test

cFisher exact test; α = 0.05

Most patients recruited for the study were living in an area of 18 × 10 sq km and they were comprised of mostly indigenous and Mexican mestizo populations. Although a higher proportion of T14 patients lived in the Tapachula City and its surrounding areas (zone 1), and a higher proportion of ISD patients lived in the foothills (zone 2) (Additional file 3), ISD and T14 patient groups had similar proportions of P. vivax cspr-msp3α genotypes (p = 0.248; Chi square test; Additional file 4). There was a significantly lower CQ dose in male patients when comparing the ISD group (median dose 0.88/IQR 0.16) to the T14 group (median dose 1.0/IQR 0.29, p = 0.01).

Clinical and parasitological clearance of the primary blood infection during 28 days

Out of 67 participants that received the initial dose of ISD, 18 (26.8 %) and 23 (34.3 %) completed the programmed follow-up visits and the flexible-schedule visits, respectively. Patients missing three continuous scheduled visits were excluded from the follow-up. Thirteen patients were not accessible for one visit during the first 14 days, and another four missed two follow-up visits. There were nine patients who withdrew, including four on day 2, two on day 3, one on day 7, and two on day 14. Six patients were not willing to be subjected to finger pricking, two moved to inaccessible communities, and another took an extra medication of CQ-PQ on day 3.

Out of 86 patients with the T14 treatment, 49 (56.9 %) completed the 14 supervised doses. Of these, 44 completed all follow-up visits (24 as programmed and 20 with the flexible schedule option, needed only for days 21 and 28). Three patients missed one visit, on day 21 or 28. There were two withdrawals of patients afraid of finger pricking on day 21.

Comparison of parasite detection by microscopy and PCR

A total of 778 samples obtained from days 2 to 28, examined by both microscopy and PCR (including three samples with only gametocytes), were used to compare the performance of the diagnostic methods. Of these, 90.3 % had concordant results (35 were positive and 703 negative for P. vivax according to both methods). There were 32 samples (4.1 %) only PCR-positive, indicating that parasite density was at the sub-microscopic level. Eight samples (1.22 %) were microscopy-positive but PCR negative. These discordant samples had parasite densities below 100/μl (16, 28, 28, 49, 70, 82, 88, and 197 p/μl). Three samples (with parasite densities below 100/μl) were positive in only one of the two thick smears.

Early clinical and parasitological responses (on days 2 and 3)

Of the T14 group, 81 and 75 were sampled during supervised treatment on day 2 and 3, respectively. For the ISD group, 57 patients were sampled on these 2 days. There were no differences in the clinical outcome between the two treatment groups (Table 2). In seven of these patients (three in the T14 group and four in the ISD group), small blisters on the lips and/or outer edges of the mouth were detected. In most of these patients, temperatures above 38 °C had been registered at recruitment/diagnosis.
Table 2

Clinical and parasitological outcome of Plasmodium vivax affected patients treated with combined doses of CQ–PQ for 14 days (T14) or with an intermittent single dose (ISD)

N

Days (mean/SD)

57e

(2/0)

59e

(3/0.15)

54

(7.2/0.74)

54

(14.6/1.1)

56

(21.4/1.2)

60

(29.8/2.9)

Single dose

 Clinical outcome (% with symptoms)

  Fever

10.17

3.70

1.8

0

0

0

  Headache

30.51

16.67

3.7

5.3

3.3

0

  Mialgias

1.69

3.39

0

0

0

0

  Arthralgias

0

0

0

0

0

0

  Blisters

5.08

6.78

7.41

3.7

1.8

0

  Erythema/pruritus

10.17

8.47

1.85

0

0

0

  Light jaundice

11.86

13.56*

11.11*

9.2*

3.6

0

 Asexual parasitaemia by microscopy

  Positivity: n, %a

14, 23.7

3, 5.0

0

0

0

2, 3.4

 p/µlb: median (IQR)c

62 (68)

157.7 (59.1)

223 (163)

% PCR positived

41.3

12.7

0

0

0

3.4

N

Days (mean/SD)

81

(2)

75

(3)

63

(7)

49

(14)

44

(21.5/1.1)

44

(29/2.5)

14-day (T14)

 Clinical outcome (% with symptoms)

  Fever

2.67

3.17

0

0

0

0

  Headache

25.33

7.94

0

2.2

0

0

  Mialgias

2.47

4.0

0

0

0

0

  Arthralgias

1.23

1.33

0

0

0

0

  Blisters

3.70

4.0

3.17

0

0

0

  Erythema/pruritus

7.41

9.33

6.35

4.1

0

0

  Light jaundice

23.46

32.0*

36.5*

40.8*

13.6

2.2

 Asexual parasitaemia by microscopy

  Positivity: n, %a

13, 16

4, 5.1

0

0

0

0

  p/µlb: median (IQR)c

118 (180)

42.4 (43.0)

  % PCR positived

34.1

8.75

0

0

0

0

N number of patients

* Statistical differences were detected on days 3 (p = 0.004), 7 (p = 0.007) and 14 (p = 0.002) in both treatment groups (Fisher exact test, α = 0.05)

 As indicated by the patients, this symptom was present between visits

an and %, number and percent of samples with asexual parasites

bNumber of asexual parasites per microlitre of blood

cOnly positive samples were included

dPercent of samples positive by molecular analysis

ePatients sampled on day 2 were not sampled on day 3 and vice versa

No difference in parasitaemia clearance was observed between treatments. Few patients had asexual blood parasites detected by microscopy on days 2 or 3 (Table 2). The reduction in the number of patients with asexual parasitaemia on day 3 with respect to day 2 was significant and similar for both treatments (T14 p = 0.000; SD p = 0.016). The number of PCR-positive samples on days 2 and 3 was higher than that determined by microscopy. On day 2, 41.3 % (1.87-fold higher than microscopy) and 34.1 % (2.3-fold higher than microscopy) of samples were PCR-positive for the ISD and T14 treatments, respectively. Persistent parasitaemia, detected by microscopy and/or PCR on days 2 and 3, was inversely correlated to the parasite count on day 0. That is, a higher parasite density (median 5068/IQR 2,067) was found on day 0 in patients that earlier cleared blood parasites, compared to the density observed (median 2891/IQR 1,357, also on day 0) in patients that on days 2 and 3 still harboured blood parasites (p = 0.0375). On the other hand, parasite persistence was not associated with parasite genotype, lower CQ doses, or patient gender or age.

Treatment failure (days 7–28)

All samples from days 7 to 21 were negative by microscopy and PCR, regardless of the treatment (Table 2). A light yellowish jaundice was observed in some ISD and T14 patients. In some ISD patients, this symptom persisted through day 14, while among T14 patients, the proportion with light jaundice increased with PQ administration (representing 40 % on day 14). No patient reported dark urine or any other clinical symptoms of haemolysis. In all patients, the jaundice disappeared by day 28, and no additional treatment was necessary. Erythema, present in some patients of both treatment schedules, disappeared after completion of the treatment. Light jaundice, erythema and/or blisters occurred concomitantly in only three patients.

Light jaundice in T14-treated patients was associated with the number of days with malaria symptoms before recruitment. The group with light jaundice had a higher proportion of patients with more symptomatic days previous to recruitment (median of days with symptoms, 16.5/IQR 2), compared to patients with no jaundice (median of days with symptoms 14/IQR 4; p = 0.0067). The presence of these symptoms was not associated with parasitaemia levels on day 0, parasite persistence (observed on days 2 and 3), gender, or PQ dosage.

T14 and ISD: prevention/elimination of recurrent blood infections (Plasmodium vivax) during 12 months

To compare the frequencies of recurrent infections for the T14 and ISD groups, only patients that completed at least 3 months of follow-up were included. Thirty-seven and 49 patients under supervised T14 and ISD treatment, respectively, met this criterion. The number of recurrent infections that occurred in patients recruited to T14 and ISD groups was truthful; the recurrences  were not associated with a particular geographic location (Additional file 5). Moreover, no differences were observed between the 18 patients that completed the semi-supervised T14 treatment and those whose doses were all supervised. All samples from these 18 patients (101 blood samples obtained from day 3 to 28) were negative by microscopy and PCR, similar to the supervised group.

The comparison between the number and timing of recurrent blood infections in the T14 versus ISD treatment group is shown in Table 3 and Fig. 2. Three patients (P3, P47, P57) under supervised T14 had a symptomatic recurrent blood infection, after asymptomatic periods of about 7–8 months (late recurrences). All these patients were affected by different P. vivax genotypes, but the genotypes of parasites during relapses were similar to those of their primary infections (homologous recurrent infections) (Table 4). Similarly, another three patients under semi-supervised T14 (P70, P113, P149) had late symptomatic recurrent blood infections (detected by microscopy) that were genetically homologous to their primary infection. No difference in the proportion and timing of recurrent episodes between supervised versus semi-supervised T14 patients was identified (p = 0.54; Additional file 6). A significantly higher number of recurrent blood infections was detected in patients under the ISD regimen (Z value 3.85; p = 0.000) (Table 3). Eighteen of the 49 patients in this group had at least one recurrent blood infection, detected by microscopy and/or PCR. The majority of the recurrent episodes were symptomatic (17 of 23), whether confirmed by microscopy and/or PCR (Table 5; Additional file 7). Upon confirmation of the first symptomatic recurrent infection, patients were immediately treated with T14. Because blood samples in asymptomatic patients were not processed immediately after sampling, some cases of recurrent parasitaemia were not opportunely detected. The recurrent cases in this group were distributed at similar frequencies of 23.3, 20, 30, and 27.7 % within the first, second, third, and fourth quarters of the year. Only 33 % (13 of 29) of recurrent blood infections coincided with the administration of the scheduled ISD dose.
Table 3

Monthly effectiveness of T14 and ISD treatments to eliminate Plasmodium vivax recurrent infections in patients of southern Mexico

A. T14; N = 37

 Day of sampling (mean/SD)

29/3

59/8

92/5

124/4

152/6

185/5

214/5

247/4

277/6

305/7

336/6

370/11

 n, samples

35

33

34

30

28

28

28

25

23

25

23

27

 n 1rst P. vivax recurrence

0

0

0

0

0

0

2

1

0

1

0

0

 Cumulative lost

0

0

0

0

0

1

3

4

4

4

5

6

 % Effectiveness

100

100

100

100

100

100

94.1

90.9

90.9

87.8

87.5

87.1

B. ISD; N = 49

 Day of sampling (mean/SD)

29/3a

62/4a

93/6

121/8

154/6

187/7a

218/7a

246/7a

278/11

306/12

336/10

367/22

 n, samples

49

48

46

42

40

39

34

28

24

24

22

20

 n, 1rst P. vivax recurrence

2

1

2

1

0

1

1

3

3

2

1

1

 Cumulative lost

0

0

0

2

2

6

9

12

12

12

12

13

 % Effectiveness

95.9

93.8

89.7

87.2

87.2

83.7

80

70.2

62.1

56.7

54

50

 P valueb

0.214

0.126

0.045

0.023

0.023

0.011

0.076

0.031

0.005

0.003

0.002

0.001

Only patients that completed at least 3 months of follow up were included in this table; four patients under T14 and 18 under ISD had at least one recurrent blood infection; a recurrent blood infection was diagnosed by RDT and/or microscopy or PCR (only two patients; P45 and P63)

Percentage effectiveness was calculated as the number of patients with no malaria infection divided by the total of patients under follow-up

N number of patients, SD standard deviation

aISD was provided

bZ-test, comparing T14 and ISD, showing the proportions of patients with recurrent infections, at 95 % confidence

Fig. 2

Cumulative incidence of Plasmodium vivax recurrences during the 12-month follow-up in groups of patients treated under supervision with combined CQ–PQ for 14 days (T14) and intermittent single doses (ISD). The CI at 95 % is shown

Table 4

Parameters of primary and recurrent Plasmodium vivax blood infections from T14 patients

Patient

Age/sex

Primary blood infection

Recurrent infection by microcopy

Serology (ELISA OD value/405NM)

mg/kg bw administered

Asexual parasitaemia (p/µl)

RFLP: cspr-msp3α/β

Daya

Presence of clinical symptoms

Asexual parasitaemia: (p/µl)

Genotype cspr-msp3α/β

CQ

PQ

P3

24/M

3177

vk210-B/III

D210

Yes

9327b

vk210-B/III

0.12D183 → 0.62 D210

25.86

3.62

P47

14/M

2119

vk210-A/I

D249

No

Mc-PCR-

0.08D187 → 1.12 D249

30.0

4.2

D279

Yes

3845b

vk210-A/I

→0.75D279

P57

50/M

2784

Vk210-K/IV

D216

Yes

2706b

vk210-K/IV

0.324D90 → 1.405D216

21.42

3.0

P61

21/F

836

Vk210-A

D95

No

Mc-/PCR−

0.49D65 → 1.67D95

28.84

4.03

D313

No

Mc-/PCR+

→1.27D313

M male, F female, RFLP restriction fragment length polymorphism, cspr circumsporozoite repeat type, msp3α merozoite surface protein 3α/β

aDay of visit/sample and diagnosis

bRDT positive and T14 given; Mc microscopy, PCR molecular diagnosis; recommended treatment: a total dose of 25 mg CQ and 3.5 mg PQ/kg bw; bw body weight

Table 5

Parameters of primary and recurrent Plasmodium vivax blood infections from ISD patients

Patient

Age/sex

Primary blood infection

Recurrent infection by microscopy

Serology (ELISA OD value/405NM; cut off value 0.25)

(p/µl) asexual parasitaemia

RFLP: cspr-msp3α/β

Daya

Clinical symptoms

(p/µl) asexual parasitaemia

Genotype cspr-msp3α/β

P6

3/F

2364

vk247-A

D241b

Yes

875

vk247-A

0.16D211 → 2.57 D241

P7

17/F

10,766

vk210-B/III

D236b

Yes

14,218

vk210-B/III

0.04D218 → 1.49 D236

P15

62/F

675

vk210-B/IV

D312b

Yes

246

vk210-B/IV

0.29D301 → > 3.0D312

P17

36/F

480

vk210/247-B/III

D108b

Yes

8485

vk247-A/I

0.18D89 → 2.1D209

P35

20/F

2241

vK210-C/V

D336b

Yes

846

vK210-C/V

0.18D308 → 1.88D336

P37

9/M

17,598

vK210-C/V

D287b

Yes

866

vK210-C/V

0.16D287 → 1.67D308

P44

60/M

2951

vk210-C/VI

D282b

Yes

844

vk210-C/VI

0.18D244 → 0.53D282

P56

42/F

7960

vk210-C/V

D178b

Yes

1570

vk210/247-A/I

0.41D147 → 1.12D178

P62

26/M

4319

vk210/247-C/II

D216b

Yes

2594

vk210-C/II

0.15D183 → 2.48 D216

P72

12/M

8059

vk210-B/III

D98c

Yes

3505

vk210-B/III

0.963D92 → 2.03D98

Truncated (complete information is given in Additional file 6)

M male, F female, RFLP restriction fragment length polymorphism, cspr circumsporozoite gene central repeat type, msp3α merozoite surface protein 3α/β genes

aDay of sample collection

bAfter diagnosed with P. vivax, T14 was administered

cContinued the ISD treatment; P44, was the only patient that had a second recurrent episode after T14 was administered; D348 was positive by microscopy

For 16 of the 20 samples from ISD patients in which the P. vivax genotype could be obtained, the primary blood infections matched their respective recurrent parasites (Table 5; Additional file 7). No association existed between the genotype and the time interval between primary and recurrent infections. That is, five patients having a primary infection with genotype cspvk210-msp3α C/msp3β V relapsed after quite different time intervals (days 32, 66, 95, 178, 287, and 352), and three patients with genotype cspvk210-msp3α B/msp3 β III also relapsed (with homologous parasites) after distinct intervals (days 74/183, 98 and 236). With all recurrent infections treated with supervised T14, the patients had no further detectable recurrent infections, with one exception (patient P44, 65 days after this treatment).

Serology

IgG antibodies against the P. vivax blood stage were detected by ELISA in 151 of 153 samples, with OD values from 0.3 to >3.0 (mean 1.14 ± 0.73) on day 7 after the initial treatment. Antibody OD values decreased post-treatment, causing nearly 50 % of the patients to be ELISA-negative within 3 months. The antibody response in two patients of the ISD group remained positive, with low OD values, until the end of the study. However, there were no clinical symptoms of a recurrent blood infection or parasitaemia (Fig. 3).
Fig. 3

IgG antibodies against the Plasmodium vivax blood stage in blood samples. a 37 patients treated with T14 and b 49 patients under ISD, during the 3–12 month follow-up. Most patients had positive ELISA OD values on day 7 after the initial treatment. Following treatment, OD values decreased or were negative, except in patients with recurrent blood infections. Squares with (+) indicate symptomatic P. vivax blood infections. Square with (×) indicate asymptomatic P. vivax that were microscopy and/or PCR-positive. The ELISA OD cut-off value is indicated with a hidden red line

In the T14 group, recurrent P. vivax blood infections were accompanied by a drastic increase in the antibody OD value, which decreased after the infection was treated with T14 (Fig. 3a). Antibody titres increased prior to the onset of clinical symptoms and/or parasitaemia. In addition, one patient (P61) likely presented asymptomatic recurrent infections, since an increased and persistently high level of antibody titres was detected on day 95–313. The sample on day 313 was also PCR-positive (Fig. 3a; Table 4). Patient P149 (semi-supervised group) had high antibody titres on days 307 and 322 (on the latter day parasite infection was detected by PCR), suggesting a long period of asymptomatic blood infection. In the ISD group, antibody responses against symptomatic and asymptomatic recurrent infections were observed (Fig. 3b; Table 5; Additional file 7), but in three patients with increased antibody OD values (P22, 0.186D315  0.57D341; P87, 0.55D121  1.73D149; P115, 0.12D115  0.90D158), it was not possible to demonstrate malaria blood infection by microscopy or PCR. No correlation was documented between the low PQ dosage in T14 or ISD and the presence of recurrent blood infections (Table 6). Interestingly, subjects affected with genotype cspvk247-msp3α/A had a serological response before their recurrent parasitaemia was detected (T14 patients P47 and P61; ISD patients P45 and P80).
Table 6

Comparison of patients with or without Plasmodium vivax recurrent blood infection and the doses of CQ and PQ managed

Treatment regimen

Patients with recurrent

P. vivax infection:

n

Total CQ dose/kg

Median(IQR)

Total PQ dose/kg

Median(IQR)

ISD

No

28a

9 (8.18–10)

0.625(0.56–0.72)

Yes

18

9.91 (9–15)

0.69 (0.6–1.0)

P valueb

0.069

0.107

T14

No

33

26.4(24–29.4)

3.75 (3.33–4.2)

Yes

4

27.3 (23.6–29.4)

3.82 (3.31–4.11)

P valueb

0.941

0.941

n number of patients, CQ chloroquine, PQ primaquine

aThree patients were not included, since after treatment they had an increase in antibody titres but there was no parasite detected by microscopy or PCR; recommended total doses: for ISD, CQ 10 mg/kg and PQ 0.75 mg/kg bw; for T14, CQ 25 mg/kg and PQ 3.5 mg/kg bw

bWilcoxon rank-sum (Mann–Whitney) test at 95 % CI

Discussion

The current findings demonstrate a lower performance in preventing relapses exerted by the ISD regimen compared to the T14 standard treatment. Nonetheless, the first ISD single dose (CQ 10 mg and PQ 0.75 mg/kg bw) effectively cleared the primary P. vivax parasitaemia, in a similar way as the first three doses of T14. The effectiveness of a single dose in clearing primary blood infections, reported earlier in El Salvador [34], Nicaragua and Costa Rica [14], could support the strategy (followed by the Mexican MCP) of giving an initial single CQ-PQ dose to patients suspected of having malaria until the parasitological diagnosis is completed. A rapid parasite clearance after the initial dose might contribute to reducing transmission, and therefore lead to a continuous reduction of malaria cases in Mexico.

The efficacy of a standard 25 mg/kg bw CQ dose to cure P. vivax infection has been proven in many different geographic sites, including Korea [35], Colombia [36], Peru [37], India [38], Pakistan [39], China [40], Thailand [41], Afghanistan [42], Vanuatu [43], Iran [44], Ethiopia [45], and Mauritania [46]. A similar clinical and parasitological outcome was found in Brazil when CQ only was administered at 10 or 25 mg/kg bw [47]. No data on the in vivo effectiveness of CQ are available in Mexico or any other country in the Americas apart from Brazil, and no P. vivax resistance to CQ has been evidenced. In this region, a combined regimen of CQ and PQ to treat malaria was introduced in the 1950s and is still effective today, probably because PQ can effectively eliminate parasites with low sensitivity to CQ [8].

Primaquine is the only licensed 8-aminoquinolone available to malaria control programmes for the elimination of liver-dwelling hypnozoites. If left untreated, hypnozoites can produce relapses upon reactivation at variable periods of time [8, 48, 49]. However, PQ-inducing acute haemolytic anaemia (AHA) in G6PD deficient individuals remains an undeniable thread [50, 51]. Thus, PQ administration is in general not recommended before G6PD testing. Nevertheless, PQ-induced AHA depends on the severity of G6PDd, which differs among the more than 180 G6PD variants and in accordance with the PQ dose administered [52]. Low PQ doses can be safely administered, and under field conditions where no G6PD tests are available, the World Health Organization has recommended a single low PQ dose (0.25 mg/kg) to eliminate P. falciparum gametocytes [8]. In Mexico, less than 1 % of the general population is G6PD deficient [1113], and the MCP has been administering 0.75 mg/kg bw PQ in a single dose in the absence of G6PD testing, without any serious AHA symptoms having been identified.

In this study, it is likely that most cases of light jaundice, detected in about 12 % of the patients recruited, were due to infected erythrocyte lysis, and others resulted from PQ administration. The condition of light jaundice occurred mostly in patients under T14 treatment. Indeed, as this treatment progressed there was a greater frequency of jaundice. Although no severe AHA was observed and light jaundice did not worsen in the participants, the current findings warrant further studies to determine G6PDd in the Mexican population affected by malaria infection, as well as its implications for treatment of the same. G6PDd screening would be facilitated by the development of diagnostic tests applicable in field conditions [53].

Mild pruritus was observed in 10 % of the patients in both treatment groups after the administration of CQ–PQ, a condition that disappeared within 1 week. CQ-related pruritus has been reported in a high proportion of Africans, in 1.9 % of Asians [54], and in Brazil [55]. Higher doses of CQ can produce paresthesia, diarrhoea, nausea, and vomiting [56], conditions not seen in patients of the present study.

Although many recurrent episodes were detected by microscopy, the serological analysis of the IgG antibody response to the P. vivax blood stage as well as the PCR diagnosis were powerful for discovering recurrent parasite exposure and/or infections, albeit retrospectively. The serological test was very sensitive to antibody titres, which increased after re-exposure to parasites (due to recurrent parasitaemia), as confirmed by PCR. Accordingly, the serological follow up confirmed parasite clearance and the absence of new blood infection. It is possible that there were some recurrent infections cleared without treatment, as evidenced by the antibody response. This situation was reported in Peru [57].

Relapse episodes represent the most important difficulty that impedes the elimination of P. vivax transmission [58]. Early relapses can appear in tropical regions as soon as 2 weeks post-primary blood infection [49, 5961]. Although the blood level of CQ was not measured in this study, other reports have estimated that CQ therapeutic concentrations may remain for 20–35 days after treatment, thus suppressing early relapse episodes [58, 6264]. In ISD patients, the first recurrent blood infections were detected on days 31 and 32, when CQ might have been at sub-therapeutic levels. The consideration of these episodes as relapses is supported by the fact that these patients had low recurrent parasitaemia and no parasites were detected, either by microscopy or PCR, seven to 21 days post-diagnosis. In T14 patients, the first recurrent blood infections were found on or after day 28 post-diagnosis. Other studies, such as those conducted in Pakistan [39] and Afghanistan [42], are also in accordance with the idea that most recurrent blood infections with P. vivax occur within 1 year of the primary infection. The low transmission rate in southern Mexico [65] makes re-infection by an infective mosquito bite unlikely. If in fact most recurrent cases found herein can be attributed to a relapse from hypnozoites in the liver, they should be caused by genetically homologous parasites [20]. Accordingly, in the present study most of the recurrent infections had the same genotype as that of the primary infection. On the other hand, there was no correlation between genotype and relapse latency.

The lack of effectiveness of the ISD regimen was evidenced by the fact that relatively few of the recurrent blood infections (33 %) were suppressed by the programmed single doses. Moreover, as these patients developed parasitaemia they might have been involved as sources of infection before the ISD was administered. The time interval from the primary to the first short- and long-term recurrent infections, as well as the overall pattern of re-infection, partially resembles the outcome reported in Central America, where P. vivax strains produced higher numbers of long-term relapse episodes. Worldwide, the T14 treatment has proven to be the most effective treatment for eliminating P. vivax relapses [9]. Since the PQ treatment was introduced in Mexico in 1959, the difficulty of completing a 14-day treatment has represented the main hurdle for malaria control. The attempts to reduce this scheme to a 5-day treatment resulted in a higher incidence of relapse [66]. Similar to India [48] and Colombia [67], in Mexico relapse episodes have occurred after short- and long-term periods of latency [20]. In the current contribution, T14 could eliminate almost 100 % of relapses occurring within 6 months and 87 % of those appearing in 12 months. T14 was less effective in Colombia, eliminating 87.4 % of relapses occurring within 4 months [68] and 85 % within 6 months [69] after treatment. In the present study, each patient with a long-term recurrent episode received the appropriate dose of PQ for his or her body weight. Therefore, relapses in these patients appear to be due to problems in drug absorption or low PQ metabolism, as observed in other regions [70, 71].

Although the efficacy of ISD for eliminating primary infections is herein documented, relapses occurred unpredictably at any time within 12 months after the first dose. This treatment scheme has been abandoned by the Mexican MCP. The present pre-elimination status of Mexico requires new strategies for the most thorough detection and treatment of cases [72]. Although the usefulness of the more efficacious T14 might be constrained by its low patient compliance, 59 % of the recruited patients complied with the supervised T14 treatment. Patients with semi-supervised regimen (with family supervision) showed similar outcomes. Hence, this alternative would increase the number of patients receiving effective treatment, and to achieve elimination of malaria in Mexico and other sites with similar epidemiological characteristics. In addition to flexibility in dose scheduling, another factor that could improve malaria control programmes is the determination of the appropriate adjustments to PQ dosing [72], which should be the subject of future studies.

Conclusions

The first dose of CQ-PQ in the ISD regimen effectively cleared primary clinical and parasitological P. vivax blood infections, in a similar way as the initial three doses of the T14 scheme. A single combined dose administered to symptomatic patients in remote areas while awaiting parasitological diagnosis may contribute to halting P. vivax transmission. The supervised T14 treatment was much more effective for preventing recurrent infections. Moreover, the semi-supervised T14 (with family supervision) was also effective for patients that did not strictly comply with the supervised scheme. On the other hand, it is clear that at the individual level, ISD scored very low compared to T14 in preventing relapses and should therefore be abandoned. Further research should be conducted to determine the ideal PQ dosing.

Abbreviations

CQ: 

chloroquine

PQ: 

primaquine

ACT: 

artemisinin-based combination therapy

AHA: 

acute haemolytic anaemia

API: 

annual parasite index

T14: 

radical treatment of 14 days

ISD: 

intermittent single dose regimen

G6PDd: 

glucose 6-phosphate dehydrogenase deficiency

bw: 

body weight

MCP: 

malaria control programme

CRISP: 

Regional Centre for Public Health Research-INSP, Mexico

PCR: 

polymerase chain reaction

RDT: 

rapid diagnostic test

WBC: 

white blood cells

ELISA: 

enzyme linked immunosorbent assay

RFLP: 

restriction fragment length polymorphism

cspr

circumsporozoite gene central repeat

msp3α

merozoite surface protein 3α gene

msp3β

merozoite surface protein 3β gene

TF: 

therapeutic failure

ACPR: 

adequate clinical and parasitological response

IQR: 

interquartile range

Declarations

Authors’ contributions

LGC participated in all aspects of the study. MHR and AFB participated in conceiving the study and its design. MHR participated in interpreting data and writing the draft. MAS and AFRL implemented the design in the field and prepared the patient information database. FSV performed the PCR diagnosis and parasite genotyping. SGV performed and coordinated microscopy analysis at INDRE. OPC performed the serologic assays. All authors read and approved the final manuscript.

Acknowledgements

This work was funded by the Pan-American Health Organization (project MEX/07/005015) and the National Institute for Public Health (project CI624). We thank the patients and their guardians for participating in the study. We are grateful to the personnel of the Malaria Control Programme at local and national levels for their facilities. Special thanks are due to Rene Torreblanca and Gerardo Espinoza at the Jurisdiction VII of Chiapas, to Héctor Olguín at CENAVECE, and to Carmen Guzman at INDRE (Ministry of Health in Mexico City). We thank José A Nettel, Ma Maura Luna and Victor H Lopez for their technical support.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Regional Centre for Public Health Research, National Institute for Public Health
(2)
Centre for Research of Infectious Diseases, National Institute for Public Health
(3)
Laboratory of Malaria, National Institute for Diagnosis and Epidemiological Reference

References

  1. Boletín Epidemiológico 1995–2005, Ministry of Health. Mexico. 2005. http://www.epidemiologia.salud.gob.mx/dgae/boletin/intd_boletin.html. Accessed 30 Sep 2015.
  2. Report on the situation of malaria in the Americas. Pan American Health Organization, Washington DC. 2011. http://www.paho.org/hq/index.php?option=com_content&view=article&id=5175%3A2010-report-on-situation-malaria-americas-2011&catid=1841%3Amalaria-publications&Itemid=40360&lang=en. Accessed 30 Sep 2015.
  3. Rodriguez MH, Betanzos-Reyes AF. Grupo de Trabajo de Malaria del Sistema Mesoamericano de Salud Pública: plan de mejoramiento del control de la malaria hacia su eliminación en México. Salud Publica Mex. 2011;53:S333–48.PubMedGoogle Scholar
  4. WHO. World malaria report 2012. World Health Organization, Geneva. 2012. http://www.who.int/malaria/publications/world_malaria_report_2012/eng/. Accessed 30 Sep 2015.
  5. Gilles HM, Warrell DA, Bruce-Chwatt LJ. Bruce-Chwatt’s essential malariology. 3rd ed. London: E. Arnold; 1993.Google Scholar
  6. Coatney GR. Pitfalls in a discovery: the chronicle of chloroquine. Am J Trop Med Hyg. 1963;12:121–8.PubMedGoogle Scholar
  7. White NJ. Drug resistance in malaria. Br Med Bull. 1998;54:703–15.View ArticlePubMedGoogle Scholar
  8. WHO. Guidelines for the treatment of malaria. World Health Organization, Geneva. 2015. http://www.who.int/malaria/publications/atoz/9789241549127/en/. Accessed 30 Sep 2015.
  9. Galappaththy GN, Omari AA, Tharyan P. Primaquine for preventing relapses in people with Plasmodium vivax malaria. Cochrane Database Syst Rev. 2007;1:CD004389.PubMedGoogle Scholar
  10. Norma Oficial Mexicana para la vigilancia epidemiológica, prevención y diagnóstico de enfermedades transmitidas por vector (NOM-032-SSA2-2002). Ministry of Health, Mexico. 2002. http://www.salud.gob.mx/unidades/cdi/nom/032ssa202.html. Accessed 30 Sep 2015.
  11. Arámbula E, Aguilar LJC, Vaca G. Glucose-6-phosphate dehydrogenase mutations and haplotypes in Mexican mestizos. Blood Cells Mol Dis. 2000;26:387–94.View ArticlePubMedGoogle Scholar
  12. Vaca G, Arámbula E, Esparza A. Molecular heterogeneity of glucose-6-phosphate dehydrogenase deficiency in Mexico: overall results of a 7-year project. Blood Cells Mol Dis. 2002;28:436–44.View ArticlePubMedGoogle Scholar
  13. Monteiro WM, Val FFA, Siqueira AM, Franca GP, Sampaio VS, Melo GC, et al. G6PD deficiency in Latin America: systematic review on prevalence and variants. Mem Inst Oswaldo Cruz. 2014;109:553–68.PubMed CentralView ArticlePubMedGoogle Scholar
  14. Bergonzoli G, Rivers Cuadra JC. Therapeutic efficacy of different antimalarial regimens in the Costa Rica-Nicaragua border region. Rev Panam Salud Publica. 2000;7:366–70.View ArticlePubMedGoogle Scholar
  15. Baird JK, Basry H, Subianto B, Fryaudff DJ, McElroy PD, Leksana B, et al. Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis. 1995;171:1678–82.View ArticlePubMedGoogle Scholar
  16. Chanon KE, Mendez-Galván JF, Galindo-Jaramillo JM, Olguin-Bernal H, Borja-Aburto VH. Cooperative actions to achieve malaria control without the use of DDT. Int J Hyg Environ Health. 2003;206:387–94.View ArticlePubMedGoogle Scholar
  17. Mendez Galvan JF, Guerrero Alvarado J, González Mora M, PerezLanda M, Quintero-Cabanillas R. Evaluation of an alternative scheme of treatment for the control of malaria. Salud Publica Mex. 1984;26:561–72.PubMedGoogle Scholar
  18. Bray PG, Deed S, Fox E, Kalkanidis M, Mungthin M, Deady LW, et al. Primaquine synergises the activity of chloroquine against chloroquine-resistant P. falciparum. Biochem Pharmacol. 2005;70:1158–66.View ArticlePubMedGoogle Scholar
  19. Murphy GS, Basri H, Purnomo Andersen EM, Bangs MJ, Mount DL, et al. Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet. 1991;341:96–100.View ArticleGoogle Scholar
  20. Gonzalez-Ceron L, Mu J, Santillan F, Joy D, Sandoval MA, Camas G, et al. Molecular and epidemiological characterization of Plasmodium vivax recurrent infections in southern Mexico. Parasit Vectors. 2013;6:109.PubMed CentralView ArticlePubMedGoogle Scholar
  21. The malERA consultative Group on Drugs. A research agenda for malaria eradication: drugs. PLoS Med. 2011;8:e1000402.PubMed CentralView ArticleGoogle Scholar
  22. Guía práctica revisada para estudios de eficacia de los medicamentos antimaláricos en las Américas. Pan American Health Organization. 2010. http://www.usaidami.org/extras/modificada-PAN-JUL-2010-integrada-2011.pdf. Accessed 30 Sep 2015.
  23. Ruebush TK 2nd, Marquino W, Zegarra J, Neyra D, Villaroel R, Avila JC, et al. Practical aspects of in vivo antimalarial drug efficacy testing in the Americas. Am J Trop Med Hyg. 2003;68:391–7.PubMedGoogle Scholar
  24. Gonzalez-Ceron L, Rodriguez MH, Betanzos AF, Abadia A. Efficacy of a rapid test to diagnose Plasmodium vivax in symptomatic patients of Chiapas, Mexico. Salud Publica Mex. 2005;47:282–7.View ArticlePubMedGoogle Scholar
  25. WHO. Methods for surveillance of antimalarial drug efficacy. World Health Organization, Geneva. 2009. http://www.who.int/malaria/publications/atoz/9789241597531/en/. Accessed 30 Sep 2015.
  26. Cucunubá ZM, Guerra AP, Rahirant SJ, Rivera JA, Cortés LJ, Nicholls RS. Asymptomatic Plasmodium spp. infection in Tierralta, Colombia. Mem Inst Oswaldo Cruz. 2008;103:668–73.View ArticlePubMedGoogle Scholar
  27. Fru-Cho J, Bumah VV, Safeukui I, Nkuo-Akenji T, Titanji VP, Haldar K. Molecular typing reveals substantial Plasmodium vivax infection in asymptomatic adults in a rural area of Cameroon. Malar J. 2014;13:170.PubMed CentralView ArticlePubMedGoogle Scholar
  28. Rubio JM, Benito A, Roche J, Berzosa PJ, Garcia ML, Micó M, et al. Semi-nested, multiplex polymerase chain reaction for detection of human malaria parasites and evidence of Plasmodium vivax infection in Equatorial Guinea. Am J Trop Med Hyg. 1999;60:183–7.PubMedGoogle Scholar
  29. Hornstein JH, Miller MJ, Thiara S. The indirect immunofluorescence (IIF) test in detection of imported Plasmodium vivax malaria in the Sutter-Yuba County area of California, U.S.A., 1975–1979. Am J Trop Med Hyg. 1983;32:1195–202.PubMedGoogle Scholar
  30. Park JW, Moon SH, Yeom JS, Lim KJ, Sohn MJ, Jung WC, et al. Naturally acquired antibody responses to the C-terminal region of merozoite surface protein 1 of Plasmodium vivax in Korea. Clin Diagn Lab Immunol. 2001;8:14–20.PubMed CentralPubMedGoogle Scholar
  31. Torres KJ, Clark EH, Hernandez JN, Soto-Cornejo KE, Gamboa D, Branch OH. Antibody response dynamics to the Plasmodium falciparum conserved vaccine candidate antigen, merozoite surface protein-1 C-terminal 19kD (MSP1-19kD), in Peruvians exposed to hypoendemic malaria transmission. Malar J. 2008;7:173.PubMed CentralView ArticlePubMedGoogle Scholar
  32. Gonzalez-Ceron L, Rodriguez MH. An enzyme-linked immunosorbent assay using detergent-soluble Plasmodium vivax antigen for seroepidemiological surveys. Trans R Soc Trop Med Hyg. 1991;85:358–61.View ArticlePubMedGoogle Scholar
  33. Yang Z, Miao J, Huang Y, Li X, Putaporntip C, Jongwutiwes S, et al. Genetic structures of geographically distinct Plasmodium vivax populations assessed by PCR/RFLP analysis of the merozoite surface protein 3beta gene. Acta Trop. 2006;100:205–12.PubMed CentralView ArticlePubMedGoogle Scholar
  34. Cedillos RA, Warren M, Jeffery GM. Field evaluation of primaquine in the control of Plasmodium vivax. Am J Trop Med Hyg. 1978;27:466–72.PubMedGoogle Scholar
  35. Lee KS, Kim TH, Kim ES, Lim HS, Yeom JS, Jun G, et al. Short report: chloroquine-resistant Plasmodium vivax in the Republic of Korea. Am J Trop Med Hyg. 2009;80:215–7.PubMedGoogle Scholar
  36. Castillo CM, Osorio LE, Palma GI. Assessment of therapeutic response of Plasmodium vivax and Plasmodium falciparum to chloroquine in a malaria transmission free area in Colombia. Mem Inst Oswaldo Cruz. 2002;97:559–62.View ArticlePubMedGoogle Scholar
  37. Graf PC, Durand S, Alvarez Antonio C, Montalvan C, Galves Montoya M, Green MD, et al. Failure of supervised chloroquine and primaquine regimen for the treatment of Plasmodium vivax in the Peruvian Amazon. Malar Res Treat. 2012;2012:936067.PubMed CentralPubMedGoogle Scholar
  38. Mishra N, Singh JP, Srivastava B, Arora U, Shah NK, Ghosh SK, et al. Monitoring antimalarial drug resistance in India via sentinel sites: outcomes and risk factors for treatment failure, 2009–2010. Bull World Health Organ. 2012;90:895–904.PubMed CentralPubMedGoogle Scholar
  39. Leslie T, Mayan I, Mohammed N, Erasmus P, Kolaczinski J, Whitty CJ, et al. A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province, Pakistan. PLoS One. 2008;3:e2861.PubMed CentralView ArticlePubMedGoogle Scholar
  40. Liu H, Yang HL, Xu JW, Wang JZ, Nie RH, Li CF. Artemisinin-naphthoquine combination versus chloroquine-primaquine to treat vivax malaria: an open-label randomized and non-inferiority trial in Yunnan Province, China. Malar J. 2013;12:409.PubMed CentralView ArticlePubMedGoogle Scholar
  41. Muhamad P, Chacharoenkul W, Rungsihirunrat K, Ruengweerayut R, Na-Bangchang K. Assessment of in vitro sensitivity of Plasmodium vivax fresh isolates. Asian Pac J Trop Biomed. 2011;1:49–53.PubMed CentralView ArticlePubMedGoogle Scholar
  42. Awab GR, Pukrittayakamee S, Imwong M, Dondorp AM, Woodrow CJ, Lee SJ, et al. Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. Malar J. 2010;9:105.PubMed CentralView ArticlePubMedGoogle Scholar
  43. Kinzer MH, Chand K, Basri H, Lederman ER, Susanti AI, Elyazar I, et al. Active case detection, treatment of falciparum malaria with combined chloroquine and sulphadoxine/pyrimethamine and vivax malaria with chloroquine and molecular markers of anti-malarial resistance in the Republic of Vanuatu. Malar J. 2010;9:89.PubMed CentralView ArticlePubMedGoogle Scholar
  44. Heidari A, Keshavarz H, Shojaee S, Raeisi A, Dittrich S. In vivo susceptibility of Plasmodium vivax to chloroquine in Southeastern Iran. Iran J Parasitol. 2012;7:8–14.PubMed CentralPubMedGoogle Scholar
  45. Teka H, Petros B, Yamuah L, Tesfaye G, Elhassan I, Muchohi S, et al. Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia. Malar J. 2008;7:220.PubMed CentralView ArticlePubMedGoogle Scholar
  46. Ould Ahmedou Salem MS, Mohamed Lemine YO, Deida JM, Lemrabott MA, Ouldabdallahi M, Ba MD, et al. Efficacy of chloroquine for the treatment of Plasmodium vivax in the Saharan zone in Mauritania. Malar J. 2015;14:39.PubMed CentralView ArticlePubMedGoogle Scholar
  47. Adelusi SA, Dawodu AH, Salako LA. Kinetics of the uptake and elimination of chloroquine in children with malaria. Br J Clin Pharmacol. 1982;14:483–7.PubMed CentralView ArticlePubMedGoogle Scholar
  48. Adak T, Sharma VP, Orlov VS. Studies on the Plasmodium vivax relapse pattern in Delhi, India. Am J Trop Med Hyg. 1998;59:175–9.PubMedGoogle Scholar
  49. Contacos PG, Collins WE, Jeffery GM, Krotoski WA, Howard WA. Studies on the characterization of Plasmodium vivax strains from Central America. Am J Trop Med Hyg. 1972;21:707–12.PubMedGoogle Scholar
  50. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blood. 2008;111:16–24.View ArticlePubMedGoogle Scholar
  51. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371:64–74.View ArticlePubMedGoogle Scholar
  52. Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI. G6PD deficiency: global distribution, genetic variants and primaquine therapy. Adv Parasitol. 2013;81:133–201.View ArticlePubMedGoogle Scholar
  53. Domingo GJ, Satyagraha AW, Anvikar A, Baird K, Bancone G, Bansil P, et al. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Malar J. 2013;12:391.PubMed CentralView ArticlePubMedGoogle Scholar
  54. Bussaratid V, Walsh DS, Wilairatana P, Krudsood S, Silachamroon U, Looareesuwan S. Frequency of pruritus in Plasmodium vivax malaria patients treated with chloroquine in Thailand. Trop Doct. 2000;30:211–4.PubMedGoogle Scholar
  55. Ballut PC, Siqueira AM, Orlando AC, Alexandre MA, Lacerda MV. Prevalence and risk factors associated to pruritus in Plasmodium vivax patientes using chloroquine in the Brazilian Amazon. Acta Trop. 2013;128:504–8.View ArticlePubMedGoogle Scholar
  56. Pinto AY, Azevedo CH, da Silva JB, de Souza JM. Assessment of chloroquine single dose treatment of malaria due to Plasmodium vivax in Brazilian Amazon. Rev Inst Med Trop Sao Paulo. 2003;45:327–31.View ArticlePubMedGoogle Scholar
  57. Delgado-Ratto C, Soto-Calle VE, Van den Eede P, Gamboa D, Rosas A, Abatih EN, et al. Population structure and spatio-temporal transmission dynamics of Plasmodium vivax after radical cure treatment in a rural village of the Peruvian Amazon. Malar J. 2014;13:8.PubMed CentralView ArticlePubMedGoogle Scholar
  58. Baird JK. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother. 2004;48:4075–83.PubMed CentralView ArticlePubMedGoogle Scholar
  59. Baird JK, Leksana B, Masbar S, Fryauff DJ, Sutanihardja MA, Suradi, et al. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg. 1997;56:621–6.PubMedGoogle Scholar
  60. Hanf M, Stephani A, Basurko C, Nacher M, Carme B. Determination of the Plasmodium vivax relapse pattern in Camopi, French Guiana. Malar J. 2009;8:278.PubMed CentralView ArticlePubMedGoogle Scholar
  61. White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J. 2011;10:297.PubMed CentralView ArticlePubMedGoogle Scholar
  62. Congpuon K, Satimai W, Sujariyakul A, Intanakom S, Harnpitakpong W, Pranuth Y, et al. In vivo sensitivity monitoring of chloroquine for the treatment of uncomplicated vivax malaria in four bordered provinces of Thailand during 2009–2010. J Vector Borne Dis. 2011;48:190–6.PubMedGoogle Scholar
  63. Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet. 1996;31:257–74.View ArticlePubMedGoogle Scholar
  64. Pussard E, Verdier F. Antimalarial 4-aminoquinolines: mode of action and pharmacokinetics. Fundam Clin Pharmacol. 1994;8:1–17.View ArticlePubMedGoogle Scholar
  65. Rodriguez MH. Malaria and dengue vector biology and control in Latin America. In: Knols BGJ, Louis C, editors. Bridging laboratory and field research for genetic control of disease vectors, vol. 11. Dordrecht: Springer; 2006. p. 129–41.View ArticleGoogle Scholar
  66. Gomez MI. Comparative study of two regimens of radical treatment of vivax malaria in Mexico. World Health Organization, Geneva. 1965. http://www.who.int/iris/handle/10665/65295. Accessed 30 Sep 2015.
  67. Blair S, Giraldo C. Reinfección endógena por Plasmodium vivax. IATREIA. 1991;4:17–21.Google Scholar
  68. Carmona-Fonseca J, Maestre A. Prevention of Plasmodium vivax malaria recurrence: efficacy of the standard total dose of primaquine administered over 3 days. Acta Trop. 2009;112:188–92.View ArticlePubMedGoogle Scholar
  69. Alvarez G, Pineros JG, Tobon A, Rios A, Maestre A, Blair S, et al. Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia. Am J Trop Med Hyg. 2006;75:605–9.PubMedGoogle Scholar
  70. Schwartz E, Regev-Yochay G, Kurnik D. Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. Am J Trop Med Hyg. 2000;62:393–5.PubMedGoogle Scholar
  71. Ingram RJ, Crenna-Darusallam C, Soebianto S, Noviyanti R, Baird JK. The clinical and public health problem of relapse despite primaquine therapy:case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea. Malar J. 2014;13:488.PubMed CentralView ArticlePubMedGoogle Scholar
  72. Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, et al. A research agenda to underpin malaria eradication. PLoS Med. 2011;8:e1000406.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Gonzalez-Ceron et al. 2015

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Advertisement